Biology and biochemistry of platelet-activating factor

O’Flaherty JT: Lipid mediators of inflammation and allergy. Lab Invest in press, 1982 Flexner S: The pathologic changes caused by certain so-called toxalbumins. Med News 65:116, 1894 Portier MM, Richet CH: De l’action anaphylactique de certains venins. Proc R Soc Lond [Biol] 54:170–172, 1902 Lewis PA: The induced susceptibility of the guinea pig to the toxic action of the blood serum of the horse. J Exp Med 10:1–29, 1908 Wells HG: Studies on the chemistry of anaphylaxis. J Infect Dis 5:449–483, 1908 Schultz WH: Physiological studies in anaphylaxis. I. The reaction of smooth muscle of the guinea-pig sensitized with horse serum. J Pharmacol Exp Ther 1:549–567, 1910 Auer J, Lewis PA: The physiology of the immediate reaction of anaphylaxis in the guinea-pig. J Exp Med 12:151–173, 1910 Andrewes FW: The behaviour of the leucocytes in infection and immunity. Lancet 2:8–16, 1910 Auer J, Robinson GC: An electrocardiographic study of the anaphylactic rabbit. J Exp Med 12:450–460, 1910 Dale HH: The anaphylactic reaction of plain muscle in the guinea-pig. J Pharmacol Exp Ther 4:167–223, 1913 Novy FG, DeKruif PH: Specific anaphylactic shock. J Infect Dis 20:776–832, 1917 Hale HH: The biological significance of anaphylaxis. Proc R Soc Lond [Biol] 91:126–146, 1920 Dale HH, Laidlaw PP: The physiological action of β-iminazolylethylamine. J Physiol (Lond) 41:318–344, 1910 Abell RG, Schenck HP: Microscopic observations on the behavior of living blood vessels on the rabbit during the reaction of anaphylaxis. J Immunol 34:195–213, 1938 Kinsell LW, Kopeloff LM, Zwemer RL, Kopeloff N: Blood constituents during anaphylactic shock in the monkey. J Immunol 41:35–49, 1941 Rose B: Studies on the histamine-content of the blood and tissues of the rabbit during anaphylactic shock. J Immunol 41:161–180, 1941 Kopeloff N, Kopeloff LM: Blood platelets in anaphylaxis. J Immunol 40:471–481, 1941 Rocha e Silva M: The role played by leucocytes and platelets in anaphylactic and peptone shock. Ann NY Acad Sci 50:1045–1064, 1950 Stetson CA: Studies on the mechanism of the Shwartzman phenomenon. Certain factors involved in the production of the local hemorrhagic necrosis. J Exp Med 93:489–503, 1951 Ebert RH, Wissler RW: In vivo observations of the vascular reactions to large doses of horse serum using the rabbit ear chamber technique. J Lab Clin Med 38:511–522, 1951 Bernauer W, Hahn F, Nimptsch P, Wissler J: Studies on heart anaphylaxis. V. Cross-desensirisation between antigen, anaphylatoxin, and compound 48/80 in the guinea pig papillary muscle. Int Arch Allergy Appl Immunol 42:136–151, 1972 Humphrey JH, Jaques R: The release of histamine and 5-hydroxy-tryptamine (serotonin) from platelets by antigen-antibody reactions (in vitro). J Physiol (Lond) 128:9–27, 1955 Waalkes TP, Coburn H: The role of platelets and the release of serotonin and histamine during anaphylaxis in the rabbit. J Allergy Clin Immunol 30:394–407, 1959 Giertz H, Hahn F, Schmutzler W, Kollmeier J: Plasma-und bluthistamin bei verschiedenen schock-formen des meerschweinschens. Int Arch Allergy Appl Immunol 25:26–45, 1964 Movat HZ, Mustard JF, Taichman NS, Uriuhara T: Platelet aggregation and release of ADP, serotonin and histamine associated with phagocytosis of antigen-antibody complexes. Proc Soc Exp Biol Med 120:232–237, 1965 Movat HZ, Uriuhara T, Taichman NS, Rowsell HC, Mustard JF: The role of PMN-leucocyte lysosomes in tissue injury, inflammation and hypersensitivity. VI. The participation of the PMN-leucocyte and the blood platelet in systemic aggregate anaphlaxis. Immunology 14:637–648, 1968 Görög P, Kovács IR: The significance of platelet aggregation in anaphylactic shock in rats. Int Arch Allergy Appl Immunol 35:411–415, 1969 Halonen M, Pinckard RN: Intravascular effects of IgE antibody upon basophils, neutrophils, platelets and blood coagulation in the rabbit. J Immunol 115:519–524, 1975 Halonen M, Fisher HK, Blair C, Butler C, Pinckard RN: IgE-induced respiratory and circulatory changes during systemic anaphylaxis in the rabbit. Am Rev Respir Dis 114:961–970, 1976 Pinckard RN, Halonen M, Palmer JD, Butler C, Shaw JO, Henson PM: Intravascular aggregation and pulmonary sequestration of platelets during IgE-induced systemic anaphylaxis in the rabbit: abrogation of lethal anaphylactic shock by platelet depletion. J Immunol 119:2185–2193, 1977 Robb HJ: The role of micro-embolism in the production of irreversible shock. Ann Surg 158:685–697, 1963 Silver MD, Stehbens WE: The behaviour of platelets in vivo. Q J Exp Physiol 50:241–247, 1965 Olsson P, Rodegran K, Taylor GA: Haemodynamic changes resulting from thrombin induced intravascular coagulation. Cardiovasc Res 4:443–451, 1970 Swedenborg J, Taylor G, Olsson P: Hemodynamic changes of adenosine diphosphate, adenosine triphosphate, and thrombin in relation to their platelet-aggregating activity. Scan J Clin Lab Invest 27:213–219, 1971 Hyman AL, Woolverton WC, Pennington DG, Jaques WE: Pulmonary vascular responses to adenosine diphosphate. J Pharmacol Exp Ther 178:549–561, 1971 Bo G, Hognestad J: Effects on the pulmonary circulation of suddenly induced intravascular aggregation of blood platelets. Acta Physiol Scand 85:523–531, 1972 Rodegran K, McAslan C: Circulatory and ventilatory effects of induced platelet aggregation and their inhibition by acetylsalicylic acid. Acta Anaesthesiol Scand 16:76–84, 1972 Vaage J, Bo G, Hognestad J: Pulmonary responses to intravascular platelet aggregation in the cat. Acta Physiol Scand 92:546–556, 1974 Lefort J, Vargafrig BB: Role of platelet aggregation in bronchoconstriction in guinea-pigs. Br J Pharmacol 55:254P-255P, 1975 Vaage J, Piper PJ: The release of prostaglandin-like substances during platelet aggregation and pulmonary microembolism. Acta Physiol Scand 94:8–13, 1975 Vargaftig BB, Lefort J, Joseph D, Fouque F: Mechanisms of bronchoconstriction and of thrombocytopenia induced by collagen in the guinea pig. Eur J Pharmacol 58:273–284, 1979 O’Flaherty JT, Cousart S, Lineberger AS, Bond E, Bass DA, DeChatelet LR, Leake ES, McCall CE: Phorbol myristate acetate: In vivo effects upon neutrophils, platelets, and lung. Am J Pathol 101:79–92, 1980 O’Flaherty JT, Craddock PR, Jacob HS: Effect of intravascular complement activation on granulocyte adhesiveness and distribution. Blood 51:731–739, 1978 Craddock PR, Fehr J, Dalmasso AP, Brigham KL, Jacob HS: Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J Clin Invest 59:879–888, 1977 O’Flaherty JT, Kreutzer DL, Ward PA: Neutrophil aggregation and swelling induced by chemotactic agents. J Immunol 119:232–239, 1977 Craddock PR, Hammerschmidt D, White JG, Dalmasso AP, Jacob HS: Complement (C5a)-induced granulocyte aggregation in vitro. A possible mechanism of complement-mediated leukostasis and leukopenia. J Clin Invest 60:260–264, 1977 Bray MA, Ford-Hutchinson AW, Smith MJH: Leukotriene B4: An inflammatory mediator in vivo. Prostaglandins 22:213–222, 1981 O’Flaherty JT, Thomas MJ, Cousart SL, Salzer WL, McCall CE: Neutropenia induced by systemic infusion of 5,12-dihydroxy-6,8,10,14-eicosatetraenoic acid. Correlation with its in vitro effects upon neutrophils. J Clin Invest 69:993–998, 1982 Henson PM: Release of vasoactive amines from rabbit platelets induced by sensitized mononuclear leukocytes and antigen. J Exp Med 131:287–304, 1970 Siraganian RP, Osier AG: Destruction of rabbit platelets in the allergic response of sensitized leukocytes. II. Evidence for basophil involvement. J Immunol 106:1252–1259, 1971 Benveniste J, Henson PM, Cochrane CG: Leukocyte dependent histamine release from rabbit platelets. The role of IgE, basophils, and a platelet-activating factor. J Exp Med 136:1356–1376, 1972 Siraganian RP, Osier AG: Destruction of rabbit platelets in the allergic response of sensitized leukocytes. I. Demonstration of a fluid phase intermediate. J Immunol 106:1244–1251, 1971 Henson PM, Cochrane CG: Immunological induction of increased vascular permeability. I. A rabbit passive cutaneous anaphylactic reaction requiring complement, platelets, and neutrophils. J Exp Med 129:153–165, 1968 Henson PM, Cochrane CG: Acute immune complex disease in rabbits. The role of complement and of a leukocyte-dependent release of vasoactive amines from platelets. J Exp Med 133:554–571, 1971 Benveniste J, Egido J, Gutierrez-Millet V: Evidence for the involvement of the IgE-basophil system in acute serum sickness. Clin Exp Immunol 26:449–456, 1976 Camussi G, Mencia-Huerta JM, Benveniste J: Release of platelet-activating factor and histamine. I. Effect of immune complexes, complement and neutrophils on human and rabbit mastocytes and basophils. Immunology 33:523–534, 1977 Cochrane CG: Role of granulocytes in immune complex-induced tissue injuries. Inflammation 2:319–333, 1977 Henson PR: Activation and densensitization of platelets by platelet-activating factor (PAF) derived from IgE-sensitized basophils. I. Characteristics of the secretory response. J Exp Med 143:937–951, 1976 Henson PM, Pinckard RN: Basophil-derived platelet-activating factor (PAF) as an in vivo mediator of acute allergic reactions: Demonstration of specific desensitization of platelets to PAF during IgE-induced anaphylaxis in the rabbit. J Immunol 119:2179–2184, 1977 Pinckard RN, Farr RS, Hanahan DJ: Physicochemical and functional identity of rabbit platelet-activating factor (PAF) released in vivo during IgE anaphylaxis with PAF released in vitro from IgE sensitized basophils. J Immunol 123:1847–1857, 1979 Benveniste J: Platelet-activating factor, a new mediator of anaphylaxis and immune complex deposition from rabbit and human basophils. Nature 249:581–582, 1974 Benveniste J, Le Couedic JP, Polonsky J, Tence M: Structural analysis of purified platelet-activating factor by lipases. Nature 269:170–171, 1977 Demopoulos CA, Pinckard RN, Hanahan DJ: Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (A new class of lipid chemical mediators). J Biol Chem 254:9355–9358, 1979 Benveniste J, Tence M, Varenne P, Bidault J, Coullet C, Polonsky J: Semi-synthese et structure proposee du facteur activant les plaquettes (P.A.F.) PAF-acether, un alkyl ether analogue de la lysophosphatidylcholine. C R Acad Sei [D] (Paris) 289:1937–1940, 1979 Hanahan DJ, Demopoulos CA, Liehr J, Pinckard RN: Identification of platelet activating factor isolated from rabbit basophils as acetyl glyceryl ether phosphorylcholine. J Biol Chem 255:5514–5516, 1980 Polonsky J, Tence M, Varenne P, Das BC, Lunel J, Benveniste J: Release of 1-O-alkylglyceryl 3-phosphorylcholine, O-deacetyl platelet-activating factor, from leukocytes: Chemical ionization mass spectrometry of phospholipids. Proc Natl Acad Sei USA 77:7019–7023, 1980 Blank ML, Synder F, Byers LW, Brooks B, Muirhead EE: Antihypertensive activity of an alkyl ether analog of phosphatidylcholine. Biochem Biophys Res Commun 90:1194–1200, 1979 Vargaftig BB, Chignard M, Benveniste J, Lefort J, Wal F: Background and present status of research on platelet-activating factor (PAF-acether). Ann NY Acad Sci 370:119–137, 1981 Goetzl EJ, Denan CK, Tauber AI, Valone FH: Novel effects of 1-O-hexadecyl-2-acyl-sn-glycero-3-phosphorylcholine mediators on human leukocyte function: Delineation of the specific roles of the acyl substituents. Biochem Biophys Res Commun 94:881–888, 1980 Czarnetzki BM, Benveniste J: Effect of synthetic PAF-acether on human neutrophil function. Agents Actions 11:549–550, 1981 O’Flaherty JT, Miller CH, Lewis JC, Wykle RL, Bass DA, McCall CE, Waite M, DeChatelet LR: Neutrophil responses to platelet-activating factor. Inflammation 5:193–201, 1981 O’Flaherty JT, Wykle RL, Miller CH, Lewis JC, Waite M, Bass DA, McCall CE, DeChatelet LR: 1-O-alkyl-sn-glyceryl-3-phosphorylcholines: A novel class of neutrophil stimulants. Am J Pathol 103:70–78, 1981 Shaw JO, Pinckard RN, Ferrigni KS, McManus LM, Hanahan DJ: Activation of human neutrophils with 1-O-hexadecyl/octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (platelet activating factor). J Immunol 127:1250–1255, 1981 Yasaka T, Boxer LA, Baehner RL: Monocyte aggregation and superoxide anion release in response to formyl-methionyl-leucyl-phenylalaine (FMLP) and platelet-activating factor (PAF). J Immunol 128:1939–1944, 1982 Stimler NP, Bloor CM, Hugh TE, Wykle RL, McCall CE, O’Flaherty JT: Anaphylactic actions of platelet-activating factor. Am J Pathol 105:64–69, 1981 Bonnet J, Loiseau AM, Orvoen M, Bessin P: Platelet-activating factor acether (PAF-acether) involvement in acute inflammatory and pain processes. Agents Actions 11:559–562, 1981 Pinckard RN, McManus LM, Demopoulos CA, Halonen M, Clark PO, Shaw JO, Kniker WT, Hanahan DJ: Molecular pathobiology of acetyl glyceryl ether phosphorycholine: Evidence for the structural and functional identity with platelet-activating factor. J Reticuloendothel Soc 28:95s-103s, 1980 Humphrey DM, Hanahan DJ, Pinckard RN: Induction of neutrophil infiltrates in rabbit skin by acetyl glyceryl ether phosphorylcholine (AGEPC). Lab Invest in press, 1982 Benveniste J: Platelet-activating factor (PAF-acether): Present status. Agents Actions 11:542–544, 1981 Burke JA, Levi R, Hanahan DJ, Pinckard RN: Cardiac effects of acetyl glyceryl ether phosphorylcholine. Fed Proc 41:823, 1982 (abstract) McManus LM, Hanahan DJ, Demopoulos CA, Pinckard RN: Pathobiology of the intravenous infusion of acetyl glyceryl ether phosphorylcholine (AGEPC), a synthetic platelet-activating factor (PAF), in the rabbit. J Immunol 124:2919–2924, 1980 Halonen M, Palmer JD, Lohman IC, McManus LM, Pinckard RN: Respiratory and circulatory alterations induced by acetyl glyceryl ether phosphorylcholine, a mediator of IgE anaphylaxis in the rabbit. Am Rev Respir Dis 122:915–924, 1980 Camussi G, Tetta C, Segoloni G, Deregibus MC, Bussolino F: Neutropenia induced by platelet-activating factor (PAF-acether) released from neutrophils: The inhibitory effect of prostacyclin (PGI2). Agents Actions 11:550–553, 1981 Lewis JC, O’Flaherty JT, McCall CE, Wykle RL, Bond MG: Platelet-activating factor effects on pulmonary ultrastructure in rabbits. Exp Mol Pathol in press, 1982 Camussi G, Tetta C, Bussolino F, Cappio FC, Coda R, Masera C, Segoloni G: Mediators of immune-complex-induced aggregation of polymorphonuclear neutrophils. II. Platelet-activating factor as the effector substance of immune-induced aggregation. Int Arch Allergy Appl Immunol 64:25–41, 1981 McManus LM, Pinckard RN, Fitzpatrick FA, O’Rourke RA, Crawford MH, Hanahan DJ: Acetyl glyceryl ether phosphorylcholine. Intravascular alterations following intravenous infusion into the baboon. Lab Invest 45:303–307, 1981 Denjean A, Arnoux B, Benveniste J, Lockhart A, Masse R: Bronchoconstriction induced by intratracheal administration of platelet-activating factor (PAF-acether) in baboons. Agents Actions 11:567–568, 1981 Vargaftig BB, Lefort J, Chignard M, Benveniste J: Platelet-activating factor induces a platelet-dependent bronchoconstriction unrelated to the formation of prostaglandin derivatives. Eur J Pharmacol 65:185–192, 1980 Crespo MS, Alonso F, Inarrea P, Egido J: Non-platelet-mediated vascular actions of 1-O-alkyl-2-acetyl-sn-3-glyceryl phosphorycholine (a synthetic PAF). Agents Actions 11:565–566, 1981 Mencia-Huerta JM, Hadji L, Benveniste J: Release of a slow-reacting substance from rabbit platelets. J Clin Invest 68:1586–1591, 1981 Shaw JO, Printz MP, Hirabayashi K, Henson PM: Role of prostaglandin synthesis in rabbit platelet activation induced by basophil-derived platelet-activating factor. J Immunol 121:1939–1945, 1978 Marcus AJ, Safier LB, Ullman HL, Wong KTH, Broekman MJ, Weksler BB, Kaplan KL: Effects of acetyl glyceryl ether phosphorylcholine on human platelet function in vitro. Blood 58:1027–1031, 1981 McManus LM, Shaw JO, Pinckard RN: Thromboxane B2 (TXB2) release during IgE anaphylaxis in the rabbit. J Immunol 125:1950–1954, 1980 Chilton FH, O’Flaherty JT, Walsh CE, Thomas MJ, Wykle RL, DeChatelet LR, Waite BM: Platelet activating factor: Stimulation of the lipoxygenase pathway in polymorphonuclear leukocytes by 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine. J Biol Chem 257:5402–5407, 1982 Lynch JM, Lotner GZ, Betz SJ, Henson PM: The release of a platelet-activating factor by stimulated rabbit neutrophils. J Immunol 123:1219–1226, 1979 Clark PO, Hanahan DJ, Pinckard RN: Physical and chemical properties of platelet-activating factor obtained from human neutrophils and monocytes and rabbit neutrophils and basophils. Biochim Biophys Acta 628:69–75, 1980 Lotner GZ, Lynch JM, Betz SJ, Henson PM: Human neutrophil-derived platelet activating factor. J Immunol 124:676–684, 1980 Betz SJ, Henson PM: Production and release of platelet-activating factor (PAF); dissociation from degranulation and superoxide production in the human neutrophil. J Immunol 125:1756–2763, 1980 Camussi G, Aglietta M, Coda R, Bussolino F, Piacibello W, Tetta C: Release of platelet-activating factor (PAF) and histamine. II. The cellular origin of human PAF: Monocytes, polymorphonuclear neutrophils and basophils. Immunology 42:191–199, 1981 Sanchez-Crespo M, Alonso F, Figido J: Platelet-activating factor in anaphylaxis and phagocytosis. I. Release from human peripheral polymorphonuclears and monocytes during the stimulation by ionophore A23187 and phagocytosis but not from degranulating basophils. Immunology 40:645–655, 1980 Tence M, Polonsky J, LeCouedic JP, Benveniste J: Release, purification, and characterization of platelet-activating factor (PAF). Biochimie 62:251–259, 1980 Mencia-Huerta JM, Benveniste J: Platelet-activating factor and macrophages. I. Evidence for the release from rat and mouse peritoneal macrophages and not from mastocytes. Eur J Immunol 9:409–415, 1979 Arnoux B, Duval D, Benveniste J: Release of platelet-activating factor (PAF-acether) from alveolar macrophages by the calcium ionophore A23187 and phagocytosis. Eur J Clin Invest 10:437–441, 1980 Arnoux B, Durand J, Rigaud M, Vargaftig BB, Benveniste J: Release of platelet-activating factor (PAF-acether) and arachidonic acid metabolites from alveolar macrophages. Agents Actions 11:555–556, 1981 Bussolino F, Benveniste J: Pharmacological modulation of platelet-activating factor (PAF) release from rabbit leucocytes. I. Role of cAMP. Immunology 40:367–376, 1980 Betz SJ, Lotner GZ, Henson PM: Generation and release of platelet-activating factor (PAF) from enriched preparations of rabbit basophils; failure of human basophils to release PAF. J Immunol 125:2749–2755, 1980 Camussi G, Tetta C, Coda R, Benveniste J: Release of platelet-activating factor in human pathology. I. Evidence for the occurrence of basophil degranulation and release of platelet-activating factor in systemic lupus erythematosus. Lab Invest 44:241–251, 1981 Lewis RA, Goetzl EJ, Wasserman SI, Valone FH, Rubin RH, Austen KF: The release of four mediators of immediate hypersensitivity from human leukemic basophils. J Immunol 114:87–92, 1975 Namm DH, High JA: Thrombin-induced formation of a polar lipid material within platelets that possesses platelet-activating activity. Thromb Res 20:285–292, 1980 Chingnard M, Le Couedic JP, Tence M, Vargaftig BB, Benveniste J: The role of platelet-activating factor in platelet aggregation. Nature 279:799–800, 1979 Chignard M, Vargaftig BB, Benveniste J, Le Couedic JP: L’agregation plaquettaire et le platelet-activating factor. J Pharmacol (Paris) 11:371–377, 1980 Vargaftig BB, Chignard M, Le Couedic JP, Benveniste J: One, two, three or more pathways for platelet aggregation. Acta Med Scand [Suppl] 642:23–29, 1980 Chignard M, Le Couedic JP, Vargaftig BB, Benveniste J: Platelet-activating factor (PAF-acether) secretion from platelets: Effect of aggregating agents. Br J Haematol 46:455–464, 1980 Chap H, Mauco G, Simor MF, Benveniste J, Douste-Blazy L: Biosynthetic labelling of platelet activating factor from radioactive acetate by stimulated platelets. Nature 289:312–314, 1981 Vargaftig BB, Chignard M, Benveniste J: Present concepts on the mechanisms of platelet aggregation. Biochem Pharmacol 30:263–271, 1981 Kravis TC, Henson PM: IgE-induced release of a platelet-activating factor from rabbit lung. J Immunol 115:1677–1681, 1975 Valone FH, Goetzl EJ: Immunologic release in the rat peritoneal cavity of lipid chemotactic and chemokinetic factors for polymorphonuclear leukocytes. J Immunol 120:102–108, 1978 Valone FH, Whitmer DI, Pickett WC, Austen KF, Goetzl EJ: The immunological generation of a platelet-activating factor and a platelet-lytic factor in the rat. Immunology 37:841–848, 1979 Camussi G, Tetta C, Deregibus MC, Bussolino F, Segoloni G, Vercellone A: Platelet-activating factor (PAF) in experimentally-induced rabbit acute serum sickness. Role of basophil-derived PAF in immune complex deposition. J Immunol 128:86–94, 1982 Lee T-C, Malone B, Wasserman SI, Fitzgerald V, Snyder F: Activities of enzymes that metabolize platelet-activating factor (1-alkyl-2-acetyl-sn-glycerol-3-phosphocholine) in neutrophils and eosinophils from humans and the effect of a calcium ionophore. Biochem Biophys Res Commun 105:1301–1308, 1982 Wykle RL, Snyder F: Microsomal enzymes involved in the metabolism of ether-linked glycerolipids and their precursors in mammals, in Martonosi A (ed): The Enzymes of Biological Membranes, vol 2. New York, Plenum Publishing Co, 1976, pp. 87–117 Hajra AK: Acyl dihydroxyacetone phosphate: Precursor of alkyl ethers. Biochem Biophys Res Commun 39:1037–1044, 1970 Wykle RL, Piantadosi C, Snyder F: The role of acyldihydroxyacetone phosphate, reduced nicotinamide adenine dinucleotide, and reduced nicotinamide adenine dinucleotide phosphate in the biosynthesis ofO-alkyl glycerolipids by microsomal enzymes of Ehrlich ascites tumor. J Biol Chem 247:2944–2948, 1972 Snyder F, Blank ML, Maline B, Wykle RL: Identification ofO-alkyldi-hydroxyacetone phosphate,O-alkyldihydroxyacetone, and diacyl glyceryl ethers after enzymic synthesis. J Biol Chem 245:1800–1805, 1970 Snyder F, Blank ML, Malone B: Requirement of cytidine derivatives in the biosynthesis ofO-alkyl phospholipids. J Biol Chem 245:4016–4018, 1970 Wykle RL, Malone B, Snyder F: Enzymatic synthesis of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine, a hypotensive and platelet-aggregating lipid. J Biol Chem 255:10256–10260, 1980 Renooij W, Snyder F: Biosynthesis of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet activating factor and a hypotensive lipid) by cholinephosphotransferase in various rat tissues. Biochim Biophys Acta 663:545–556, 1981 Mueller HW, O’Flaherty JT, Wykle RL: Ether lipid content and fatty acid distribution in rabbit polymorphonuclear neutrophil phospholipids. Lipids 17:72–77, 1982 Benveniste J, Chignard M, Le Couedic JP, Vargaftig BB: Biosynthesis of platelet-activating factor (PAF-acether) II. Involvement of phospholipase A2 in the formation of PAF-acether and lyso-PAF-acether from rabbit platelets. Thromb Res 25:375–385, 1982 Ninio E, Mencia-Huerta JM, Heymans F, Benveniste J: Biosynthesis of platelet-activating factor. I. Evidence for an acetyl-transferase activity in murine macrophages. Biochim Biophys Acta 710:23–31, 1982 Alonso F, Gil MG, Sanchez-Crespo M, Mato JM: Activation of 1-alkyl-2-Iyso-glycero-3-phosphocholine: Acetyl-CoA transferase during phagocytosis in human polymorphonuclear leukocytes. J Biol Chem 257:3376–3378, 1982 Mencia-Huerta JM, Ninio W, Roubin R, Benveniste J: Is platelet-activating factor (PAF-acether) synthesis by urine peritoneal cells (PC) a two-step process? Agents Actions 11:556–558, 1981 Blank ML, Lee T-C, Fitzgerald V, Snyder F: A specific acetylhydrolase for 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (a hypotensive and platelet-activating lipid). J Biol Chem 256:175–178, 1981 Lee T-C, Blank ML, Fitzgerald V, Snyder F: Substrate specificity in the biocleavage of theO-alkyl bond: 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (a hypotensive and platelet-activating lipid) and its metabolites. Arch Biochem Biophys 208:353–357, 1981 Farr RS, Cox CP, Wardlow ML, Jorgenson R: Preliminary studies of an acid-labile factor (ALF) in human sera that inactivates platelet-activating factor (PAF). Clin Immunol Immunopathol 15:318–330, 1980 Wykle RL, Kraemer WF, Schremmer JM: Specificity of lysophospholipase D. Biochim Biophys Acta 619:58–67, 1980 Blank ML, Cress EA, Whittle T, Snyder F: In vivo metabolism of a new class of biologically active phospholipids: 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine, a platelet activating-hypotensive phospholipid. Life Sci 29:769–775, 1981 Godfroid J-J, Heymans F, Michel E, Redeuilh C, Steiner E, Benveniste J: Platelet activating factor (PAF-acether): Total synthesis of l-O-octadecyl-2-O-acetyl-sn-glycero-3-phosphoryl choline. FEBS Lett 116:161–164, 1980 Tokumura A, Fukuzawa K, Isobe J, Tsukatani H: Lysophosphatidic acid-induced aggregation of human and feline platelets: Structure-activity relationship. Biochem Biophys Res Commun 99:391–398, 1981 Lee T-C, Malone B, Blank M, Snyder F: 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) stimulates calcium influx in rabbit platelets. Biochem Biophys Res Commun 102:1262–1268, 1981 Hanahan DJ, Munder PG, Satouchi K, McManus L, Pinckard RN: Potent platelet stimulating activity of enantiomers of acetyl glyceryl ether phosphorylcholine and its methoxy analogues. Biochem Biophys Res Commun 99:183–188, 1981 Wykle RL, Miller CH, Lewis JC, Schmitt JD, Smith JA, Surles JR, Piantadosi C, O’Flaherty JT: Stereospecific activity of 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine and comparison of analogs in the degranulation of platelets and neutrophils. Biochem Biophys Res Commun 100:1651–1658, 1981 Satouchi K, Pinckard RN, Hanahan DJ: Influence of alkyl ether chain length of acetyl glyceryl ether phosphorylcholine and its ethanolamine analog on biological activity toward rabbit platelets. Arch Biochem Biophys 211:683–688, 1981 Wykle RL, Surles JR, Piantadosi C, Salzer WL, O’Flaherty JT: Platelet activating factor (1-O-aIkyl-2-O-acetyl-sn-glycero-3-phosphocholine). Activity of analogs lacking oxygen at the 2-position. FEBS Lett 141:29–32, 1982 Tence M, Coeffier E, Heymans F, Polonsky J, Godfroid J, Benveniste, J: Structural analogs of platelet-activating factor (PAF-acether). Biochimie 63:723–727, 1981 O’Flaherty JT, Salzer WL, Cousart S, McCall CE, Piantadosi C, Surles JR, Hammett MJ, Wykle RL: Platelet-activating factor and analogues: Comparative studies with human neutrophils and rabbit platelets. Res Commun Chem Pathol Pharm 39:291–309, 1983 Satouchi K, Pinckard RN, McManus LM, Hanahan DJ: Modification of the polar head group of acetyl glyceryl ether phosphorylcholine and subsequent effects upon platelet activation. J Biol Chem 256:4425–4432, 1981 Heymans F, Michel E, Borrel M-C, Wichrowski B, Godroid J-J, Convert O, Coeffier E, Tence M, Benveniste J: New total synthesis and high resolution H NMR spectrum of platelet-activating factor, its enantiomer and racemic mixtures. Biochim Biophys Acta 666:230–237, 1981 Camussi G, Bussolino F, Tetta C, Brusca R, Ragni R: The binding of platelet-activating factor (PAF) to polymorphonuclear neutrophils (PMN) as a trigger for the immune-induced PMN aggregation. Pa Med 22:1–5, 1980 Shaw JO, Henson PM: The binding of rabbit basophil-derived platelet-activating factor to rabbit platelets. Am J Pathol 98:791–810, 1980 Valone FH, Coles E, Reinhold VN, Goetzl EJ: Binding of the platelet-activating factor 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphorylcholine (AGEPC) by human platelets. Fed Proc 41:733, 1982 (Abstract) O’Flaherty JT, Lees CJ, Miller CH, McCall CE, Lewis JC, Love SH, Wykle RL: Selective desensitization of neutrophils: Further studies with 1-O-alkyl-sn-glycero-3-phosphocholine analogues. J Immunol 127:731–737, 1981 O’Flaherty JT, Swendsen CL, Lees CJ, McCall CE: Role of extracellular calcium in neutrophil degranulation responses to 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine. Am J Pathol 105:107–113, 1981 Cazenave J-P, Benveniste J, Mustard JF: Aggregation of rabbit platelets by platelet-activating factor is independent of the release reaction and the arachidonate pathway and inhibited by membrane-active drugs. Lab Invest 41:215–225, 1979 O’Flaherty JT, Wykle RL, Lees CJ, Shewmake T, McCall CE, Thomas MJ: Neutrophil-degranulating action of 5,12-dihydroxy-6,8,10,14-eicosatetraenoic acid and 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine. Comparison with other degranulating agents. Am J Pathol 105:264–269, 1981 Smith RJ, Bowman BJ: Stimulation of human neutrophil degranulation with 1-O-octacecyl-2-O-acetyl-sn-glyceryl-3-phosphocholine: Modulation by inhibitors of arachidonic acid metabolism. Biochem Biophys Res Commun 104:1495–1501, 1982 Chesney CM, Pifer DD, Byers LW, Muirhead EE: Effect of platelet-activating factor (PAF) on human platelets. Blood 59:582–585, 1982 O’Flaherty JT, Hammett MJ, Shewmake TB, Wykle RL, Love SH, McCall CE, Thomas MJ: Evidence for 5,12-dihydroxy-6,8,10,14-eicosatetraenoate as a mediator of human neutrophil aggregation. Biochem Biophys Res Commun 103:552–558, 1981 O’Flaherty JT, Wykle RL, McCall CE, Shewmake TB, Lees CJ, Thomas M: Densensitization of the human neutrophil degranulation response: Studies with 5,12-dihydroxy-6,8,10,14-eicosatetranoic acid. Biochem Biophys Res Commun 101:1290–1296, 1981 Henson PM, Oades ZG: Activation of platelets by platelet-activating factor (PAF) derived from IgE-sensitized basophils. II. The role of serine proteases, cyclic nucleotides, and contractile elements in PAF-induced secretion. J Exp Med 143:953–968, 1976 Haslam RJ, Venderwel M: Inhibition of platelet adenylate cyclase by 1-O-alkyl-2-O-acetyl-sn-glyceryl-3-phosphorylcholine (platelet-activating factor). J Biol Chem 257:6879–6885, 1982 Shukla SD, Hanahan DJ: AGEPC (platelet-activating factor) induced stimulation of rabbit platelets: Effects on phosphatidylinositol, di- and tri-phosphoinositides and phosphatide acid metabolism. Biochem Biophys Res Commun 106:697–703, 1982